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Tourette syndrome is a complex neurodevelopmental disorder that causes significant
morbidity for pediatric and adult patients and is present in up to 1% of the population. Genetic,
functional and volumetric analyses suggest that the core neuropathology of Tourette syndrome
resides within the dysfunctional cortico-striato-thalamo-cortical circuitry of the basal ganglia.
Patients can have 5% smaller striatal volumes when compared to age-matched controls and up to
60% reductions in small populations of regulatory interneurons concurrent with severe clinical
symptomatology. These interneurons are thought to regulate the immense cortical input that is fed
into the striatum and modulate depolarization of neighboring medium spiny neurons as they form
output to the globus pallidus. The goal of this work is to recapitulate interneuron loss in patients
with severe tics and create an animal model for Tourette syndrome.
Our group combined the regional specificity of stereotactic plasmid delivery with the
cell-type specificity of transgenic cre mice in order to induce the expression of diphtheria toxin
receptor in only those striatal interneurons genetically engineered to express cre-recombinase.
Recombination of a lox-flanked diphtheria toxin receptor gene will activate protein production
only in these interneurons, inducing receptor expression and then selective apoptosis after
systemic diphtheria toxin administration. This system allows the behavioral consequences of
interneuron ablation to be studied aside from perioperative inflammation of virus injection and
with the temporal control of distant intraperitoneal diphtheria toxin injection.
Pre-pulse inhibition is the ability to reduce the ‘startle’ response to a stimulus of high
amplitude when another stimulus of lower intensity is given immediately beforehand. It is a
quantitative behavioral assay that is deficient in patients with Tourette syndrome and mice treated
with high dose amphetamines. Its neurocircuitry is thought to be based in the syncytium of the
striatal interneurons of the basal ganglia, and deficiencies of behavioral inhibition are thought to
lie along the spectrum of sensorimotor-gating abnormalities inherent to Tourette syndrome.
We demonstrated consistent diphtheria toxin receptor expression specific to the
acetylcholine-expressing interneurons of the striatum. After diphtheria toxin was administrated to
a subset of mice two weeks post-operatively, a reduction in prepulse inhibition was seen as
compared to the toxin-naive controls in the cohort. The ablation of these cells was confirmed via
immunohistochemistry of the sectioned striatal tissue and the degree of interneuron loss appeared
to correlate with behavioral alterations seen on prepulse testing over the course of 7 weeks.
Future goals of our work include: understanding the downstream neurochemical changes
that may ensue from striatal interneuron loss, studying the compensatory mechanisms which may
reverse symptomatology over time, assessing the validity of this model using medications
classically used to treat symptoms in Tourette syndrome (typical and atypical antipsychotics, α2agonists), and ultimately trialing novel therapeutics to better treat patients in the future.
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I. Introduction

The purpose of this work is to elaborate on a recent finding which posits a
pathophysiological explanation for the symptoms of Tourette syndrome. Using a
vector-mediated gene delivery technique to impair key regulatory neurons in the
striatum, we hope to replicate an interneuron deficiency which is thought to be the
pathophysiological basis for Tourette syndrome, and create an animal model that
will allow us to better understand symptomatology. While we try to emulate
findings discovered in human patients, we are aware that the sheer complexity of
the disorder limits our model to only a face-valid representation of the difficulties
that individuals must live with. We hope that this model will allow us to test novel
therapeutics that can manage symptoms, understand natural compensatory
mechanisms that some patients exhibit, and learn more about opportunities to
intervene early in presentation in order to mitigate the disorder’s course.

Tourette Syndrome
Tourette syndrome (TS) is a complex neuropsychiatric developmental disorder
found in up to 1% of children. (1, 2) Clinical features that establish a TS diagnosis
include: multiple motor tics, at least one vocal tic, a fluctuating course of symptoms
which occur each day for the period of at least 1 year, onset before the age of 21, and
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associated symptoms cannot be explained by any other medical or psychiatric conditions
such as autism-spectrum disorder, Parkinson’s disease, Sydenham’s chorea or the
controversial Pediatric Autoimmune Neuropsychiatric Disorder associated with
Streptococcal Infections. (3, 4, 5) A qualified observer is necessary to make a diagnosis.
Chronic Tic Disorder, characterized by either motor or vocal tics (but not both)
and Transient Tic Disorder, defined as tics present for less than one year, are thought to
be other Tourette-spectrum disorders with a lifetime prevalence of up to 5% and 20%,
respectively. (6) Up to 60% of TS patients suffer from comorbid Attention-Deficit
Hyperactivity Disorder, a disorder characterized by inattentiveness, over-activity, and
impulsivity, and 30% from Obsessive-Compulsive Disorder, known for the intrusive
thoughts and repetitive behaviors that lend name to the disorder. In fact, only 10–20% of
children with TS are free of a co-morbid disorder. (7, 8, 9)
Learning disabilities and deficiencies in fine motor control, motor inhibition, and
habit learning are among the behavioral abnormalities documented in TS. (10, 11, 12)
The association of these behaviors with the basal ganglia, (13, 14) and the efficacy of
dopamine D2 antagonists in treating symptoms have suggested that the core of TS
pathophysiology may lie in the developing mesolimbic system, specifically in the
striatum, the largest nucleus of the basal ganglia. (15, 16)
Gilles de la Tourette first described a case series of 9 patients in 1885 who had
brief, repetitive, stereotyped, and fragmented movements that seemed to mimic isolated
components of normal behavior. (17) The elemental unit of Tourette syndrome thus
became the ‘tic’. Motor tics include eye blinking, shoulder shrugging, head jerking,
posturing, or self-harming behaviors, or any combination thereof (among many others).
Vocal tics can include (but are not limited to) throat clearing, yelling, humming, guttural
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sounds, or more complex arrangements such as in echolalia, palilalia or coprolalia.
Echolalia matches the processing of a single auditory stimulus with the creation of an
identical, almost reflexive response, while palilalia matches similarly an entire phrase or
sentence. (18) Coprolalia is the spontaneous selection and expression of language from a
reservoir of inappropriate words, often sensationalized by depictions of TS in the media.
While it is true that these utterances are non-volitional and largely beyond the
individual’s control, it is untrue that they are as common as depicted, and they only affect
around 30% of patients. (19)
Commonly, tics are noticed by parents first between the ages of 4 and 6 and have
the highest incidence between the ages of 7 and 9. In fact, by age 11, 96% of patients
experience symptoms. (20, 21) Motor symptoms progress rostrocaudally, can become
more complex with age and commonly occur 1-2 years before vocal tics, which often
occur between the ages of 9 and 11. Tic severity is worst between the ages of 7 and 15,
but by age 18, 55% of adults experience reduction in symptoms to ‘minimal’ or ‘absent’
levels. Comorbid OCD and ADHD symptoms also subside in parallel as children reach
the end of their teenage years. (22) In fact, only 5% of individuals report symptoms
worsening after adolescence, and fewer than 20% of children continue to experience a
moderate impairment of global functioning as a result of their symptoms at age 20. (23).
TS is understood to be a largely pediatric developmental phenomenon that in some is
compensated for by mechanisms yet unknown, but in others persists as a beating drum of
sensorimotor activation. (24)
Tics are typically preceded by ‘premonitory urges’, well defined as sensations in
the anatomical distribution of an oncoming tic, perceived by a patient before they actually
start ticcing. (25, 26, 27) Premonitory urges are thought to be the awareness of initial
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internal stimuli sequentially before they manifest into an actual tic, similarly to the
feeling of an itch before it materializes into a scratch. Like an itch, premonitory urges
can be resisted and the corresponding tics thereby temporarily suppressed. (25, 26)
However, it is very difficult to completely silence a premonitory urge without a tactile
“response” stimulus or satisfying movement. The awareness of the premonitory urge
increases with age, and up to 90% of patients are aware of their premonitory urges 3
years after diagnosis. (28)
A specialized form of cognitive behavioral therapy, Habit Reversal Therapy has
shown efficacy similar to our best pharmacological therapeutics and utilizes the
awareness of this premonitory urge. (29, 30, 31) Patients are taught to first pay attention
to the onset of their premonitory urge, and complete a competing response movement to
provide stimulus necessary to silence the urge without performing the tic. Competing
response movements are practiced, “antagonistic” movements that are incompatible with
a tic, such as holding the chin to the chest in order to quell an urge for a head jerking tic.
The efficacy of Habit Reversal suggests that a mechanism may exist for cognitive control
of the sensorimotor gating abnormalities of Tourette syndrome and which is utilized by
non-pharmacological therapeutics such as cognitive behavioral therapy. In fact, tics are
commonly known to fluctuate with mood, concentration, sleep, and various social and
environmental factors. (32) TS has come to be understood as far more than just a roster of
tics, but in fact an intricate system of abnormal sensation and responses which is
influenced by both the individual and the outside world.
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Genetic Correlations
TS inheritance is complex and is the result of yet undefined contributions from
each parent. (33, 34) 10 to 100-fold increases in TS have been demonstrated in
individuals who have first-degree relatives with the disorder as compared to individuals
in the general population, and chronic tic disorder documented in 7% to 22% of
individuals with first degree relatives who have TS. (35) Monozygotic twins demonstrate
a 50-70% concordance for Tourette syndrome and 77% for chronic tic disorder, while
these values are 9% and 23% respectively for dizygotic twins. (36) An association has
been found with mutations of the gene SLITRK1 on chromosome 13q31.1, which is
thought to play a role in dendritic growth and neuronal migration. (37) SLITRK1 is
expressed in areas commonly associated with TS, such as cortex, hippocampus, thalamic,
subthalamic and globus pallidus nuclei, striatum, and cerebellum. (38) However, a
substantial number of individuals with TS do not demonstrate mutations in the SLITRK1
gene, and therefore it remains an uncommon cause of the disorder.
Abnormalities in striatal dopamine balance are well-established in Tourette
syndrome, and have been the basis for treatment with atypical and typical antipsychotics
such as risperidone and haloperidol. (39, 40) Examination of our genome for
polymorphisms on genes coding for dopamine-regulating proteins has yielded
associations between symptomatology and dopamine receptor subtypes found in the
striatum, globus pallidus, subthalamic nucleus and the substantia nigra. (41, 42, 43, 44)
During my undergraduate experience at Johns Hopkins, I worked in Dr. Harvey Singer’s
lab to first describe polymorphisms on the dopamine transporter gene associated with TS
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in a cohort of 266 individuals with the disorder, as compared to age-matched controls.
(45) Despite this evidence, some studies with focused regions of analyses demonstrate
no association between polymorphisms on certain dopamine receptor genes and the
tyrosine hydroxylase gene in TS. (46) The genetics of TS, as they relate to dopamine
regulation and in general are complex and much work remains to be done in order to
understand what role they play in the genetic predispositions and clinical manifestations
of this disorder.
A recent discovery by researchers at Yale described a family in which 8
offspring inherited a severe form of TS from their father, who were all found to share a
common mutation on the gene coding for histidine decarboxylase. (47) This enzyme
converts histidine to histamine, a neurotransmitter not previously thought to play a role in
the pathophysiology of TS. As a result of this discovery, a great deal of interest has been
focused on describing the mechanism by which mutations on the histidine decarboxylase
gene result in the symptomatology of severe Tourette syndrome.

The Basal Ganglia
Genetic,

functional

and

anatomical

data

suggest

that

the

core

neuropathophysiology of Tourette syndrome resides within the dysfunctional corticostriato-thalamo-cortical circuitry of the basal ganglia. (48) The basal ganglia constitute a
system of nuclei with anatomic origins in the mesencephalon (substantia nigra pars
compacta and reticulata), the diencephalon (the subthalamus and thalamic nuclear
targets), and the telencephalon (the caudate, putamen [collectively termed the striatum]
and the internal and external segments of the globus pallidus). The broad anatomical
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extent of this system speaks to its integral role in regulating behaviors, thoughts and
emotions.
The striatum is composed of the distinct caudate and putamen nuclei, which share
significant intercommunication across the intervening anterior segment of the internal
capsule (which contains several additional motor and non-motor tracts), and serves as an
input nucleus into the basal ganglia. It receives massive cortical input in four classicdescribed parallel cortical-subcortical circuits: a motor circuit from the supplementary
motor, premotor, and primary motor cortices, an occulomotor circuit from the
supplementary eye fields and frontal eye fields, an executive function circuit from the
dorsolateral prefrontal and the lateral orbitofrontal cortices, and an emotional/limbic
component from the medial orbitofrontal cortex, the hippocampus and the nucleus
accumbens. A point should be made that these tracts are far from the discrete, parallel
‘loops,’ as they are described above
heuristically,

but

interconnected

rather

functional

deeplynetworks

which cannot be thought of as only a
collection separate entities, but rather
as a single, cohesive network.
The

caudate

and

putamen

project to the globus pallidus (GP) and
Figure 1. Schematic of the basal ganglia circuitry. Blue
arrows are inhibitory synapses, red arrows excitatory
synapses and pink arrows dopaminergic projections.
Globus pallidus pars externa, GPe. Subthalamic nucleus,
STN. Globus pallidus pars interna, GPi. Substantia nigra
pars compacta, SNc. Substantia nigra pars reticulate, SNr.

substantia nigra pars reticulate (SNr)
via the classical direct and indirect
pathways. In the diagram to the left, blue
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arrows denote inhibitory synapses, the red arrows excitatory synapse, and the pink arrow
dopaminergic projections. The direct pathway is conceptually thought of as the cortical
stimulation upon the striatum which directly and selectively inhibits the GPi, freeing the
anterior nuclei of the thalamus from GPi inhibition in order to promote movement in the
‘go’ pathway. The indirect pathway is thought of as a ‘no-go’ circuit that inhibits the
GPe’s inhibition of the subthalamic nucleus, which then stimulates the GPi to inhibit the
thalamus and prevent movement and thought. The GPi serves as an output structure for
both circuits and plays a role in coordinating their spatial and temporal convergence,
before sending output to the anterior thalamic nuclei, which then broadly project back
onto the cortex to initiate or inhibit action. (49)
Dopaminergic projections of the substantia nigra onto the striatum facilitates
movement in the direct pathway via excitatory G-protein-coupled D1 receptors and
through inhibitory G-protein-coupled D2 receptors in the indirect pathway. When
dopamine depletion occurs, Parkinsonism characterized by bradykinesia and rigidity
arises. TS, in contrast, is a hyperkinetic movement disorder and the model outlined above
clarifies why dopamine D2 blockade, which should increase activity in the indirect
pathway, is of therapeutic benefit in reducing excessive movement. The regulatory
control of dopamine at the level of the striatum is thought to play a role in modulating the
immense executive and sensorimotor information arising from the cortex, and the
improper balance of this neurotransmitter system, its role on the direct and indirect
pathways and on the functionality of the striatal circuitry as a whole is thought to result in
at least some of the symptoms of TS, OCD and ADHD.
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Striatal Interneurons
In the late 1990’s, advances in neuroimaging permitted new insight into the
anatomical pathology of TS. Volumetric MRI scanning of the striata of patients with
severe TS and their age-matched controls demonstrated a 5% reduction in the caudate
volumes of the TS individuals. (50, 51) While only a small difference, this consistently
replicated finding focused attention on the neurocircuitry of the basal ganglia, specifically
the striatum as a locus of pathology in TS. The distinct populations of neurons and
interneurons within the striatum were closely studied in the context of TS in order to
explain the results of these volumetric analyses.
80% of the human striatum is composed of a single type of inhibitory,
GABAergic neuron, termed the medium spiny neuron (MSN) (52, 53) MSNs in the
striatum receive massively convergent input from cortical neurons and are arranged in
two functional and anatomical compartments. The matrisomal MSNs receive input from
motor, cognitive and associative systems and comprise the bulk of the striatal mass, while
striosomal MSNs receive input from limbic and hippocampal areas and are interspersed
throughout the matrix. The remaining striatal neurons are comprised of at least 3 different
populations of ‘interneurons’ interspersed among the MSNs. Each expresses various
intracellular proteins and neurotransmitters which contribute to their classification. These
include

fast-spiking

acetylcholine-containing

GABA-ergic

parvalbumin-positive

tonically-active

neurons

(TANs),

neurons
which

(FSNs)
are

and

heavily

interconnected with neighboring MSNs. FSNs demonstrate burst-like activation with
stable inter-spike intervals, (54, 55, 56) while TANs are more constitutively activated at
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baseline, but exhibit variable firing patterns as well. (57, 58) These interneurons
communicate with one another via gap junctions, potentially forming a functional
syncytium, and are hypothesized to shape and synchronize MSN activity in response to
cortical input.
FSNs form functionally connected units with each other and silence 25-75% of
the hundreds of neighboring MSNs during choice-selection tasks in rats. In a study
published in Neuron, single unit recording electrodes were placed bilaterally in the striata
of mice and the animals were taught to make left/right decisions to receive a reward. (59)
MSN-MSN pairs demonstrated highest activation rates when the animal chose to the
ipsilateral side, and FSN-MSN pairs showed greater activation during contralateral
selection. While MSN-MSN activation has been described as being a “winner take all”
phenomenon with interconnection both sparse and unidirectional, FSN-MSN connectivity
is broad, temporally-linked and perisomatic, and may play a large role in modulating
global MSN activity. (60)
TANs exhibited synchronized pausing of their tonic activation immediately
before reward receipt in reinforcement experiments, termed “conditioned pause
response.” (61) TANs also synapse directly onto projections from the substantia nigra
and stimulate both dopamine release and inhibition with single pulse and repeated pulse
depolarization, respectively. (62) TAN firing pauses synchronously with burst firing of
dopamine neurons in behaving animals, speaking to the coordination and interrelatedness
of these two modulatory signals on striatal activity, and the impact of these interneurons
on reward conditioning and action coordination in animals.
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In 2006, Leckman et. al. (55) composed the diagram below to organize the
information regarding striatal wiring. Massive cortical input from motor, cognitive and
associative systems synapse onto FSNs and a network of neighboring MSNs located in
the matrisomal compartment of the striatum. Limbic and hippocampal areas synapse onto
the MSNs and TANs of the striosomal compartment (SS) of the striatum, interspersed
within the larger matrix of striatal neurons. While the details of the compartmentalization
of the striatum are beyond the scope of this thesis, they are described here to simply
elaborate

upon

the

modulatory impact these
interneurons
striatal

have

output,

Image removed in consideration of US
Copyright Law

on
and

demonstrate the highly
complex,

interwoven

anatomy of the various
functional
which

networks

compose

the

striatum and ultimately
form our behavior.

Figure 2. Diagram outlining the general circuitry of the striatum, its cortical input
and its output targets. Striosomal MSNs, SS, receive limbic input and matrisomal
MSNs, MS, receive cortical input. Fast-spiking parvalbumin-positive interneurons,
FSN, and Tonically-active interneurons, TAN, synapse on both populations of
neighboring MSNs to mediate output from the striatum. Globus pallidus pars
interna, GPi. Substantia nigra pars reticulata, SNr. Globus pallidus pars externa,
GPe. Subthalamic nucleus, STN. Substantia nigra pars compacta, SNc.

Tourette syndrome and the Striatum
In 2005, port-mortem analyses of 3 patients with severe TS symptoms
demonstrated a 50% reduction in FSNs in the caudate nucleus and a 30-40% reduction in
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the putamen. (63) The same study also showed an increase (120%) in the number of
inhibitory neurons of the GPi. A more recent study replicated the 50-60% reduction of
FSNs, but additionally demonstrated the loss of cholinergic TANs between striatal
compartments in 5 patients who had severe TS symptoms. (64) No difference was found
in the number or distribution of MSNs or in the cytoarchitecture of the striatal
compartments. The loss of these interneurons in TS was speculated to play a role in the
dysfunctional pruning of cortical input and the formation of resultant thalamic output, the
degrees of which lie along the spectrum of disorder associated with Tourette syndrome.
We aim to model the pathophysiology of Tourette syndrome by recapitulating this
neuropathological change in mice. While animal models cannot fully recapitulate the
consequences of these pathological changes in the human, this model will advance our
understanding of the disorder and the testing of novel therapeutics. Similar advances
have been achieved using neuropathologically-based models of several other
neuropsychiatric conditions, even in the absence of clear etiological understanding. For
example, models of chronic stress and early-onset Alzheimer’s disease have led to
considerable insight into our understanding of depression and Alzheimer’s, respectively,
and have provided templates for our hypothesis-driven use of new treatment modalities to
manage the progression of symptoms. (65, 66, 67) Similarly, significant work has also
been done to understand Parkinson’s disease utilizing etiologically-neutral models of
dopamine depletion as induced by administration of the toxin MPTP. (68) This model has
allowed for the investigation of new pharmacological treatments in Parkinson’s disease,
as well as the development of non-pharmacological therapeutics such as deep brain
stimulation. (69) While we have yet to understand how or why these pathological
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changes occur in TS, having a workable mouse model would provide us the opportunity
to test novel therapeutic strategies in the future.
Targeted ablation of striatal interneurons raises daunting technical challenges.
Genetic targeting using parvalbumin or acetylcholine promoters would have extensive
effects throughout the central nervous system and periphery, not limited to only these
cells. Conversely, local infusion of a nonspecific virus or of a pharmacological agent
lacks cell-type specific targeting. The technical constraints of single neuron ablation in
the living mouse are beyond the capabilities of modern neurosurgical technique.
We have developed a combination strategy, using viral-mediated gene delivery to
interneurons in transgenic mice, making these cells uniquely susceptible to apoptosis
after a systemic toxin injection. Transgenic mice express the cre recombinase in targeted
populations of interneurons, as well as other cells in the body, using the parvalbumin and
choline acetyltransferase (ChAT) promoters. Stereotactic viral injections are targeted to
the striata of these transgenic mice. As described below, our viral constructs contain a
simian diphtheria toxin receptor (DTR) gene in a backwards orientation, which is
inverted and activated only in cells that co-express cre recombinase. Therefore, while all
infected cells in the target region will express the plasmid, only those that co-express cre
recombinase will express functional DTR proteins on their surfaces. Consequently, these
striatal interneurons will be uniquely susceptible to ablation after systemic administration
of diphtheria toxin (DT), to which murine cells are otherwise resistant. Using this
previously developed DT/DTR system and virus-mediated gene delivery, we unite the
regional specificity of stereotactic injection with the cell-type specificity of transgenic
expression, in order to replicate the prevailing pathophysiological basis for
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symptomatology in Tourette syndrome. Timed ablation of these cells using this system
will also permit serial monitoring of behavioral assays in order to determine any resulting
functional changes and study them in a development context.

Adeno-associated Virus and Gene Delivery
These experiments critically depend on recombinant adeno-associated virus
(AAV), the details of which figure prominently in the technical development of our
approach, as described below. AAV was first described in 1965 as a contaminant of
adeno virus cultures. Co-infection with adenovirus or herpes virus is necessary for lytic
cycle induction. Its prevalence is high in the general population, as almost 80% of
individuals can be seropositive at any given time. It is not known to be linked with
disease if lone infection occurs, and AAV2 use as a gene therapy vector has already been
established in human subjects. (70, 71)
AAV has a small 4.7 kb single stranded DNA sequence with 125 palindromic
base pair flanking sequences that allow it to fold upon itself in a spiral T shaped
configuration. (71) Its relatively small genome contains several genes with variablesplice transcription and their products play multiple roles in viral replication. Its genome
does not code for a polymerase, and it must therefore hijack a cellular polymerase in
order to replicate. In fact, its entire genome consists only of a cap (capsid) sequence,
which undergoes variable splicing in order to create 3 proteins which form the capsid,
and several rep (replication) genes which mediate both polymerase binding to the
terminal repeat sequences and DNA integration into the host’s genome during its
lysogenic phase.
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During infection, the AAV genome is integrated specifically and consistently on
chromosome 19q13.3. This behavior is unique among all eukaryotic viruses and results
from its mimicking of a homologous human DNA sequence in order to find its insertion
site. This specificity mitigates concerns that arise with other vectors regarding the risk of
DNA strand breakages from variable insertion into other more critical genes, or at key
polymerase-binding sites. These properties have made the AAV the most attractive tool
for clinical transgene therapy to date.
Much work has been done to develop recombinant AAV technology as a tool for
gene therapeutics and intracellular protein production. (72, 73, 74) At least 10 serotypes
have been identified and subtypes 2 and 10 are most commonly used in the CNS because
of their tropism for neural tissue. Genes that have been substituted for viral proteins show
stable expression within host cells for significant amounts of time, where it is found as
either a double stranded integrated sequence, converted from its single stranded plasmid,
or as a circular exosome, which is also transcriptionally active.
While its main drawback is a small genome that limits the size of the transgene
that can be inserted in its plasmid, the safety and efficacy of this emerging technology
have fueled the use of AAV gene therapy in several mouse models, as well as in human
phase I and II trials for Parkinson’s disease, cystic fibrosis, hemophilias A and B and
Canavan’s disease (a fatal pediatric inherited disorder associated with mutations in genes
regulating aspartic acid metabolism). (75, 76, 77, 78, 79) The promise of this new
technology to treat and understand human disease has broad implications for the future of
gene therapy and medicine as a whole.
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Project Goals
The goal of this work, which constitutes the first 18 months of a larger multi-year
project, was to use AAV technology to induce the selective ablation of striatal interneurons
of the mouse in order to model the pathophysiology of Tourette syndrome, and to begin the
preliminary behavioral analyses to assess the consequences of these ablations. While the
DTR/DT system has previously used in mice, it was our task to construct an iDTR plasmid
that would respond to cre induction. After this was achieved, which required iterative
modification over several generations of plasmids, we tested our system in vitro in cell
culture, and in-vivo in glial cells and interneurons. Once stable DTR expression was
achieved, we aimed to test the efficacy of DT delivery to induce cell death in vitro, in vivo,
and secondarily through our examination of behavioral effects. Well-established behavioral
assays of striatum-dependent procedural memory, amphetamine-induced stereotypy, and prepulse inhibition were (and continue to be) used to determine any Tourette-like phenotypic
effects of the ablation of both parvalbumin-positive FSNs and acetylcholine-positive TANs.
These behavioral assays are described at greater length below.
In future years of this project, the predictive validity of this model will be assessed by
determining the response of observed TS-like behaviors to standard pharmacological therapy
for Tourette syndrome, including antipsychotics and centrally-acting α2 agonists. The
response to these medications will establish the predictive validity of this model, setting the
stage for further work to develop and test novel therapeutics. Parallel efforts will also be
made to determine the downstream effects of these interneuron ablations on functional and
neurotransmitter systems, as well as their developmental course when initiated in adolescent
mice in order to determine the adaptive neurochemical mechanisms that may result.
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II. Methodology

Plasmid Construction
We engineered a recombinant adeno-associated virus to allow for the creregulated expression of the diphtheria toxin receptor (DTR) in targeted cells in vitro and
in vivo.
The cre-lox system functions through the specific enzymatic activity of crerecombinase on lox DNA sequences. Cre (causes recombination) is a protein of 343
amino acids whose catalytic site is on the c-terminus of its 4 subunit domain, similar to
the ‘integrase’ family of enzymes. Cre cleaves DNA at specific lox sequences (locus of
X-over P1, first discovered in the bacteriophage P1), which are 34 bp long and contain a
central 8 bp sequences flanked by two palindromic 13 bp sequences. Cre binds to two of
these sites and recombines the double stranded DNA via a Holliday intermediate. If the
two lox-p sites are in opposite orientations, recombination will cause inversion of the
intervening DNA, while lox-p sequences in the same orientation will induce segment
deletion. We utilized both of these strategies, as further described below. After
recombination, Cre unbinds the lox sites and resolvases and ligases quickly re-establish
competent, contiguous DNA, leaving behind a single residual lox-P site.
Plasmid construction began with an AAV-kreb vector, obtained from
collaborators, which served as the backbone for our construct, contained a transcription
initiation site, and coded for an ampicillin-resisting beta-lactamase gene used for
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selection in bacteria during cloning. We were able to integrate into this vector two pairs
of oppositely configured lox sites by methods described below, and ligate in between
them an inducible DTR cassette. Our first step was to create a sufficient supply of this
vector for our future work.
The plasmid was transformed into Invitrogen One Shot® Top10 chemicallycompetent E.coli (Invitrogen, California), heat shocked at 42° for 30 seconds to promote
internalization of the DNA, and left to shake 1 hour before the bacteria were plated on a
ampicillin-containing LB-agar plate. Viable colonies were taken from the plate after 48
hours and inoculated into 1ml Invitrogen Gibco® LB broth, left to shake for 8 hours, then
diluted into 100ml broth and left to shake overnight under antibiotic selection. Bacterial
cells were then harvested by centrifuge at 6000g for 15 minutes and the resulting pellet
was then transferred to an Endofree® Plasmid Purification Kit (Qiagen, Maryland) for
retrieval of an adequate supply of the plasmid for our subsequent experiments.
A gene for green florescent protein gene, EGFP, was obtained from collaborators
and was replicated performing PCR amplification on a standard reaction mixture of
DNTPs, H2O, Taq buffer, Taq polymerase, and a primer set which would read the AscI
cleavage site on one of its ends and the NheI, HpaI, NdeI sites on its other. The AscI and
NheI sites would be used to integrate this sequence into the AAV vector. After PCR, the
reaction mixture was placed in a 1.5% supra sieve agarose gel and run at 100mv for 90
minutes. The gel around the electrophoresed band of proper length was excised from the
whole gel and a Quiaquick® Gel Extraction Kit (Quiagen, Maryland) was used to extract
the DNA from the agarose.
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The AAV vector and the EGFP PCR product were then placed in 2 separate
reaction mixtures of 1 microliter (µl) each of AscI and NheI restriction enzymes, 2 µl of
NEB4 buffer, 0.2 µl of BSA buffer and 17 µl of water each for a total reaction mixture of
20µl. The enzyme-induced cleavage resulted in “sticky” ends for both the vector and the
EGFP gene, and the vector was treated with 0.5 ul CIP (calf intestinal phosphatases) for 1
hour at 37 degrees to prevent autoligation onto itself. Gel electrophoresis was then
performed in 1% agar at 110 mv for one hour on both mixtures in order to separate out
the purified AAV vector and EGFP gene. Each was extracted and combined in a reaction
mixture containing 1µl each of a T4 ligase and its buffer in water for 4 degrees overnight
in order to induce ligation of the sticky ends of the gene into the vector. The products
were electrophoresed, extracted and then transformed into commercial stbl3 E. coli
(Invitrogen One Shot®) via heat shock, shaken and then plated onto an ampicillinpositive agar plate at 37 degrees overnight. After centrifuging, a bacterial pellet was
transferred to a Quiaprep® Spin Miniprep Kit so that the plasmid product could be
purified. Enzymatic testing with AscI, HpaI and NdeI, and primer pair matching across
ligation sites demonstrated a single fragment of the expected transcript length via both
PCR and electrophoresis.
We next obtained a DTR gene from another adjacent lab. A sequence was added
to this gene by Meiyu Xu coding for flag (flu antigen) so that this small amino acid chain
would be translated at the end of the DTR protein and serve as a target for high-affinity
anti-flag antibodies used to detect the DTR protein during immunohistochemical analyses
of cells and tissue. The new DTR-flag gene was replicated via PCR using primer pairs
which bound to sequences at either of its ends, one containing an HpaI site and the other
an NdeI site. The mixture was placed in a Biorad C1000 Thermo cycler at an annealing
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temperature of 55 degree for 30s, at 32 cycles and the product was then incubated with
HpaI and NdeI enzymes at 37 degrees for two hours. The use of this restriction enzyme
pair would allow for insertion of the DTR-flag gene into the larger plasmid in the desired
reverse orientation relative to the direction of transcription. The AAV-EGFP plasmid was
then lysed with the same restriction enzymes set, both vector and insert ligated (with the
addition of Vaccinia topoisomerase I for higher efficiency), and the product transformed
in stbl3 E. coli and purified. Restriction enzyme testing (NheI and NdeI), as well as
whole plasmid sequencing confirmed the proper integration of the DTR gene and
demonstrated a new AAV-GFP-DTR-flag plasmid (iDTR2).
Once construction was confirmed, we used an Endotoxin-free® maxiprep kit to
harvest a large yield of replicated iDTR2 plasmid for use in the transfection of PC12
cells. An aliquot of the plasmid was also taken and titrated to a concentration of 1x1012
genomic copies per ml and sent to the Salk Institute (California) for packaging in an
rh10AAV vector. As we waited for the recombinant virus, in vitro testing in
pheochromocytoma (PC12) cells proceeded.

Cellular Transfection
The PC12 line of cells is derived from a pheochromocytoma of the adrenal
medulla of the rat. Upon administration with NGF, cells begin forming dendritic
arborizations, start to resemble sympathetic neurons and form vesicles of dopamine and
norepinephrine. It has been a well established neural cell line since its first description in
1976. (80)
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A 1ml aliquot of PC12 cells (Sigma-Aldrich, St. Louis, MO) were thawed from
deep freeze and diluted in 10ml serum-positive Invitrogen Gibco® Optimem I growth
media in a Falcon tube. The solution was centrifuged at 200g for two minutes and the
supernatant was removed. The pellet was resuspended in 10ml growth media and plated
on a CellBIND® surface cell culture dish (Corning, NY). Cells were visualize under the
light microscope and left to incubate at 37 degrees celcius and 5% CO2 for 48 hours.
Cells were passaged every 2-3 days by first confirming their adherence to the
collagn coated plate, suctioning their media, washing them with 5ml PBS and then
removing their adherence to the plate by bathing them in 1ml of Invitrogen Gibco®
TrypLE-express trypsin. After the cells sat for 2 minutes, they were observed under the
microscope and shaken gently to detatch any still adherent cells. 5 ml of growth media
was added and the suspension was pipetted into a new falcon tube. The solution was
contrifuged and the supernatant vacuumed. The cell pelette could now have been diluted
to any concentration, plated on collagen-coated microscope slides, and transfected with
various plasmids.
For transfection, cells were plated at a concentration of 1x105 cells/ml onto a
collagen coated microscope slide partitioned in 4 equal sections. The cells were left to
incubate overnight in order to promote adherence to the slide and acclimation to the new
media. When 80-90% confluence of cells was achieved in each slide section, transfection
proceeded. First, 1 or 2µl of iDTR2 plasmid was added to an eppendorf tube containig
100µl of optimem media. For certain slide sections, 1ul of our GFP-cre containing
plasmid (the cre source which contained a green marker) was also added. A PUC17
plasmid, an inert strand of DNA was added as needed to ensure that the same amount of
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DNA was included into each slide section. For each section, either iDTR2 and PUC17,
GFP-cre and PUC17, or iDTR2 and GFP-cre was added to a 100µl aliquot of growth
media. The mixtures were left to sit for 5 minutes, while 4ul of Invitrogen lipofectamine
LTX® was added to a separate 100µl of growth media. (Lipofectamine is a lipid-based
compound used to shuttle DNA into cells in a nonpolarized form.)
The DNA/media and Lipofectamine/media mixtures were then combined after 5
minutes and left to sit at room temperature for an additional 30 minutes. This facilitated
the binding of the lipofectamine to the DNA and each mixture was then added to its
respective cell section. After 48 hours, flourscence was observed under a microscope in
order to detect green from either the EGFP gene of the iDTR2 cassette or from the GFPcre plasmid in selected cells, and demonstrate the absence of fluorescence under control
conditions.
The general form of our transfection experiments included the 8 different
experimental groups outlined in chart 1 below. The first set of cells served as controls
and were not treated with any DNA. The second set were transfected with the inert
PUC17 plasmid and GFP-cre, and the third with the iDTR2 plasmid and PUC17. The
Group 1,2

Group 3,4

Group 5,6

Group 7,8

DT + 

No DNA

PUC17+cre

iDTR+PUC17

iDTR+cre

DT - 

No DNA

PUC17+cre

iDTR+PUC17

iDTR+cre

Chart 1. Experimental design of analyses testing the DTR/DT system in transfection of PC12 cells with cre, iDTR
and PUC17 plasmids. Each cell represents a well of PC12 cells transfected with the plasmids indicated, and
subsequent exposure to DT.
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final group had both the iDTR2 and cre plasmids transfected. Multiple slides were made
of this form and then to a subset DT was subsequently added.
Cells were immunostained at various time intervals after transfection and DT
administration in order to detect intracellular proteins (DTR, caspase proteins as
apoptosis markers) or then run in a cell death assay in order to observe the relative cell
viability between different experimental conditions.

Apoptosis Assay
Half of the cells used for each apoptosis assay were treated with DT in
concentrations from 1nM to 1µM, as these doses have been reported to be efficacious in
inducing cell apoptosis in DTR-transfected cells (81). Reagents from an MTT cell death
assay kit were added to the media of all cells and colorimetric analysis was performed to
test for cell viability. The MTT assay works by detecting the amount of remaining viable
intracellular enzymes (hexosaminidases); the greater the number of viable proteins, the
greater the color change to a deep purple, while the greater the number of apoptotic cells,
the weaker the absorption of the purple by the spectrophotometer.
Cells were grown in Corning® CellBIND® surface 96-well plates and transfected
with plasmids under multiple conditions as outlined above (12 wells/condition). They
grew for 48 hours and a percentage began expressing visible GFP on fluorscent
microscopy. Two days later, they were washed in PBS and the media changed. DT was
added to the cells the following day and left in the media for 4 hours. MTT (3-(4,5
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was then added to the mixture.
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(Roche Pharmaceuticals, Mannheim, Germany) MTT is a yellow compound which, when
reacted on by hexosaminidase, is converted to purple formazan, changing the reaction
mixture color. MTT was placed on the cells for 4 hours, and then a buffer solution was
added overnight which assists in dissolving the insoluble purple formazan into the
reaction mixture. The following day, the absorbance of the colored solution at 562 nm
was measured by a Gen 5® spectrophotometer. The relative absorbance of this
wavelength is inversely correlated to the number of apoptotic cells by this measure.

Stereotactic Virus Delivery
Surgical procedures were performed in full compliance with IACUC protocols
and every effort was made to optimize the peri-operative care of the animals. A log was
kept documenting the details of each procedure, animals were monitored closely for
several days post-operatively and saline/dextrose supplementation was managed
judiciously, if it was warranted. Every effort was made to minimize any pain or harm to
the animals studied in our analyses.
A dedicated surgical procedure room was prepared in a sterile manner. Mice were
transported to this space and given several minutes to acclimate. Each was injected
intraperitoneally with 5mg/kg of the anxiolytic rimodyl at a volume of 0.5ml at least 15
minute before any other procedure was performed. A viral vector at a concentration of
1x1012 GC/ml (or saline for controls) was drawn into a 0.5µl Hamilton syringe. After 15
minutes, the mice were injected with ketamine/xylazine intraperiotnealy at a
concentration of 100mg/10mg/kg in a volume of 0.3ml. After anesthesia was confirmed
by a tail pinch with forceps, the mice’s eyes were covered with lubricant in order to
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prevent dessication. Their scalps were shaved and were positioned and centered in a
mouth bar and ear holders on a Digital Lab Standard® stereotactic frame (Stoelting Co.,
Wood Dale, IL). The incision site was washed with an alcohol prep pad and a sterile
razor blade was used to make 2cm mid-saggital incision. Retracting clips were placed on
the skin and underlying tissue dissected away. The injection syringe was centered at
bregma, the intersection of the coronal and saggital sutures. The stereotactic frame was
zeroed at this point and the needle was translated to the lambdoid suture in order to
straighten the head position and ensure that rotation in the superior/inferior and
medial/lateral directions was minimized. The syringe was then returned to bregma, the
frame rezeroed and two coordinates 0.74 mm anteriorly and 2.3 mm bilaterally in the
medial/lateral direction were targeted in order to provide a straight trajectory to the core
of the striata. The mouse was tested for any locomotor response to a mildly aversive
stimulus at this time and given a small bolus of anesthetic if it was warranted.
A high speed drill was used to create a perpendicular 1mm burr hole at this
position and the injection needle was advanced to a depth of 3.0mm. It was held here for
a minute before continuous infusion of the virus was started at 0.1 µl/min for 10 minutes
via programmable Micro4® microsyringe infusion pump (World Precision Instruments,
Sarasota, FL), for a total volume of 1 µl. After injection was complete, the syringe was
left in placed for an additional 5 minutes in order to optimize delivery and minimize
reflux during steady syringe withdrawal. The contralateral side was also injected with 1
µl of the virus, and all mice were injected subcutaneously with 0.5 ml saline during the
course of the surgery in order to supplement fluid balance.
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The incision was closed with 6.0 nylon suture. Mice were placed in a heated cage
post-operatively and provided with moistened food and water in containers on the cage
floor. Each was given sufficient time to recover post-operatively, and supplemented with
saline or dextrose if they appeared overly dehydrated or lethargic. Mice were returned to
the animal care facility and monitored daily for several days post-operatively.
Wild type, C57BL/6J mice (Jackson Labortatories, Bar Harbor, ME) and our inhouse GS-cre and Chat-cre transgenic mice were injected with various combinations of
our virus-bound iDTR plasmids in order to demonstrate the utility of our DTR/DT system
and learn from the behavioral consequences that resulted from its use.

Tissue Preparation
For analysis of virus-mediated DTR gene delivery by immunohistochemistry,
each brain was removed and quickly fixed in a solution of 4% paraformaldehyde/PBS for
24 hours, and then equilibrated in a 30% sucrose solution for 48 hours.
After 48 hours, the brains were brought to a Leica Jung® SM2000R microtome
and placed on dry ice for a minimum of 10 minutes in order to allow them to solidify.
The microtome stage was allowed to equilibrate to -16 degrees Celcius using a
Physitemp® BFS-3MP temperature controller and each brain was postitioned as if the
mouse was laying supine with the most rostral portion of its head facing the ceiling. The
brain was steadied in this position by coating its base in two thin layers of the sucrose
solution and then the microtome advanced in order to section the striatum in 40 µm-thick
sections. Each successive slice was placed in series in wells of a Corning 12-well plate,
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filled with cryoprotectant solution (30% glycerin, 30% ethylene glycol, 0.2x PBS), The
plates were placed in a 4 degree refrigerator and the slices were then ready for
immunostaining after being washed with PBS.

Immunohistochemistry
Cells, and brain slices transferred to mesh cups using a paintbrush were washed 3
times in PBS for 5 minutes each. The cells and slices were then blocked in 10% Serum,
0.2% Triton (Sigma) and 0.1% Tween 20 (Sigma) in PBS for 30 minutes. Another wash
performed, and the cells/tissue were then bathed in a solution containing PBS, the
primary antibody (details listed below), 5% serum, 0.2% Triton, and 0.1% Tween 20.
They were placed in a 4 degree refrigerator overnight. The next day, 3 washes with PBS
were performed for 5 minutes each and then a secondary antibody was applied in 10%
serum, 0.2% Triton, 0.1% Tween 20 and PBS. The choice of secondary antibody was
based on the wavelength of fluorescent emission desired (488=green, 594=red), and the
antibody’s disimilarity to the primary antibody in regards to species of origin, so the Fc
portion of the primary antibody was recognized as foreign. Several subsequent washes
removed any unbound, free secondary antibody and the specimen was mounted on glass
slides with Vectashield mounting medium (Vector Labs, Inc, Burlingame CA). The
preparations were viewed on a Nikon upright flourescent microscope.
Primary antibodies used in our analysis of cell cultures and tissues
transfected/infected with our plasmid included: anti-flag (mouse, Sigma f1804) at a
concentration of 1:500 in order to detected DTR-flag in culture and tissue, anti-caspase
(rabbit, Abcam ab44976) at a concentration of 1:1000 in order to detect apoptotic caspase
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proteins in cell cultures, anti-GFP (chicken, Abcam ab13970) at 1:2000 dilution in order
to accenuate plasmid induced GFP expression in brain tissue and cells, and anti-chat
(goat, Chemicon ab144p) at 1:500 in order to detect choline expressing TANs in the
striatum. Secondary antibodies used to visualize primary antibody binding included: antimouse fluor 594 (Invitrogen, allo32), anti-rabbit fluor 594 (Invitrogen, a11037), antichicken fluor 488 (Invitrogen, all039), anti-goat fluor 488 (Invitrogen), all at
concentrations of 1:400 in PBS.
In some experiments we used 3,3’-diaminobenzidine (DAB) precipitation to
visualize antibody staining. DAB provides an opaque stain for ready visualization using a
light microscope and is particularly useful for low-magnification images. The initial
washing and blocking steps are the same as above for this VECTASTAIN® Elite ABC
reagent protocol. The primary antibody is added after 30 minutes of blocking in rabbit
serum and incubated overnight at 4 degrees. The same primary anti-ChAT antibody is
used and a biotinylated secondary antibody is added in a 1:500 concentration the
following day, after two washes to remove any excess primary antibody. After another
two washes to remove the unbound secondary antibody, the VECTASTAIN® Elite ABC
reagent is added, which binds to the biotin of the specialized secondary antibody. After
one more wash, the DAB solution is added; the peroxidase from the ABC reagent reacts
with it, producing the opaque, insoluble precipitate. The tissues are then washed in water,
counterstained and mounted on glass slides for analysis.
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Behavioral Analyses
The design, production, and testing of our DTR plasmid in vitro and in vivo took
more that the allocated year for my participation in this project, but because of a strong
interest in this project, I injected our iDTR3 virus (described below) into the striata of
transgenic ChAT-cre mice (later treated with DT) on which we could pilot our behavioral
analyses.
Pre-opretaive and post-operative mice were brought to a dedicated room with a
SRA-Lab Pre-pulse Inhibition chamber (SD Instruments, San Diego, California). The
chamber consisted of a 6” (L) x 2 1⁄4” (internal diameter) Plexiglas tube on a stage under
which a piezoelectric accelerometer was attached. The chamber was both illuminated and
sound attenuated, and a speaker providing both high and low amplitude stimuli was
located 33mm directly above the cylinder.

Mouse movements were detected and

transduced by the accelerometer and then digitized and stored on an attached computer
via a compatible Startle program (SD Instruments). Pre-pulse programing and testing was
performed according to a previous described protocol. (82)
64 startle readings were obtained per mouse, per trial, under 5 different
experimental conditions: no stimulus, pulse alone, 6 decibel pre-pulse, 12 decibel prepulse and 16 decibel pre-pulse. Broad-band background noise of 65 decibels was present
throughout. The trial began with a 5 minute acclimation period, after which a set of
pulse-only trials were used to obtain baseline startle readings. These trials consisted of
the background noise pierced by a sudden 120 decibel pulse, with subsequent recording
of the startle response. Afterwards, randomized pulse only, pre-pulse (all decibel levels),
and no pulse conditions were delivered over the course of 21 minutes, with an average 15
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second breaks between each trial. The pre-pulse rounds consisted of 20ms long prepulses
delivered at each of the three decibel levels, 200 ms before the startle stimulus. The
mouse’s startle amplitude was recorded for up to 50 ms after the 120 decibel pulse was
delivered, in order to obtain a startle response only immediately relevant to the delivered
stimulus. The no stimulus conditions consisted of only the broad band background noise
and were used as a measure the mouse’s baseline activity.
Data was then collected for each mouse and formatted to produce an output file in
Excel which documented baseline, mean and peak velocity measurements. Time points
for maximal startle response and soonest response after pulse delivery were also
documented. These data were ordered by trial, and mean startle amplitudes at baseline
and between pre-pulse conditions were calculated. Pre-pulse inhibition was computed as
the percent difference in startle amplitude for a given condition as compared to the
baseline startle response. Lower startle amplitudes in the pre-pulse conditions indicated
an inhibition. Data was aggregated across multiple experimental conditions and groups in
order to provide mean startle and pre-pulse inhibition values for each mouse and for each
group. Statistical distribution was reported as the standard error of the mean.
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III. Results

Figure 3 depicts the first generation DTR plasmid, iDTR1. Its lox sites are in the
same orientation, which induce segment deletion in the presence of cre, and are denoted
by the black arrows. A red fluorescent protein (RFP) sequence is downstream to a stop
cassette, both found within an intervening sequence flanked by two lox sites, or ‘floxed’.

Figure 3.. First generation iDTR plasmid, iDTR1.

In the absence of cre, transcription initiates at the CMV promoter, continues
through lox 1 to the RFP sequence, and ends upon transcribing the stop cassette. In the
presence of cre recombinase, the floxed cassette is excised, leaving behind a single lox-P
lox
site and allowing expression of the iDTR gene. This first generation plasmid was
developed before my work began on this project. While it demonstrated expected
function in PCR analysis of fragment length alteration with variable primer set under
Cre+ and Cre- conditions, as well as adequate RFP expression in transfected cells, it did
not adequately express RFP after in
in-vivo
vivo stereotactic infection of striatal interneurons,
and thus necessitated a re
re-working of its construct.
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iDTR2
Figure 4 depicts our second generation plasmid, iDTR2, which I assisted in
constructing and took a lead role in testing both in vitro and in vivo.. It utilizes the ability
of cre to invert the sequence between two lox sites in opposite orientations.

This

inversion is made irreversible
versible through the use of two distinct lox sites, loxP and lox2722,
as further described below.

Figure 4.. iDTR2 plasmid. Dark and light gray rectangles represent two pairs of matching lox sites. After
recombination, the two unm
unmatched
atched lox sites remain on the plasmid as labeled.

An elongation factor promoter is depicted most upstream of the construct and
initiates transcription. Lox2722 (number one) is read upstream to loxP (number two), and
transcription continues to EGFP, a gen
genee which codes for a green fluorescent protein. In
the cre-negative
negative strand at the top of this image, an inverted, untranslatable DTR sequence
is then read. Transcription continues through the pairing lox2722 and loxP sites (numbers
three and four) to WPRE ((woodchuck hepatitis post-transcriptional
transcriptional regulatory element),
element) a
stabilization sequence used to enhance transcription efficiency in mammalian cells
c
(83).
The plasmid concludes with a poly
poly-A
A site. In the presence of cre, the EGFP-DTR
EGFP
cassette
is inverted, activating
tivating DTR expression and inactivating EGFP.
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The double lox sites in this construct render the inversion irreversible. The
mechanism of this effect merits further explanation. With one pair of lox sites in
opposing orientations, the cassette has the potential to flip back and forth indefinitely.
Therefore in the presence of cre, the cassette with one set of opposing lox sites will be as
likely to be in the reverse orientation as in the forward direction, as recombination can
occur continuously.

Figure 5.. Intermediate formed during recombination of the iDTR2 plasmid. As the cassette is recombined, lox sites
3 and 4 are displaced upstream and lox site 2 downstream on the plasmid.

However, with the two lox sites as they are cur
currently
rently positioned, the result of a
flip of the entire sequence between the dark gray bars (for instance) in Figure 4 will result
in a dark gray lox site positioned in between two light gray lox sites, as shown in Figure
5. In addition, the light gray lox ssite
ite (number 3) will now be in the same direction relative
to its complementing site, number 1. This would result now in the deletion of the
intervening sequence between the two light gray lox sites, resulting in the removal of the
dark gray lox site, and the
he replacement of the entire excised sequence with only a single
light gray lox site remaining in its place (number 1). Two incompatible lox sites will thus
remain, one at either end of the now inverted DTR
DTR-GFP
GFP cassette. Segment recombination
will stall and thus DTR translation will primarily occur in the presence of cre.
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To demonstrate that the floxed cassettes recombined in the presence of cre and
worked as we envisioned, PCR analysis of the plasmid was performed by selecting a
primer pair that would allow for exponential copying only when recombination of the
floxed cassette by cre occured
occured.. The primers included one on the woodchuck stabilization
sequence in the backward direction (towards the cassette) and a forward EGFP3F primer
that would also bind in an upstream direction when the cassette was unflipped. The
following diagram demonstrates the primer pair and its binding.

Figure 6. Second generation iDTR plasmid with primer binding sites for experimental testing of recombination in
the presence of cre
cre-recombinase, via the polymerase chain reaction.

This relative configuration
nfiguration of primers will cause the PCR transcripts to be
produced at a linear rate because only by binding to primer 2 will both primer sites be
available for transcription during the next round of the cycle. The transcription product
would also be significantly
ificantly shorter when polymerase binds to primer 1 rather than primer
2, and these two different bands would be separated out during electrophoresis. When
the cassette ‘flips’ in the presence of cre
cre-recombinase,
recombinase, each polymerase binding event
will result in a transcript that contains both primer sites. The rate of product formation
increases exponentially, and will result in a single fragments of uniform length, thus
confirming the recombination of our plasmid.
Figure 7 demonstrates our primer pair recombination analysis. Each oddodd
numbered lane contained the plasmid alone, and each even
even-numbered
numbered lane contained the
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plasmid and cre. The final two lanes
contained cre only and water as a
control, respectively. The specific
appearance of a band of the predicted
length only in the cre-containing
containing lanes
confirmed that recombination of this
selected,

purified

plasmid

was

occuring in response to cre
cre, as
planned. The
he activation of DTR by cre
recombinase in this iDTR2 plasmid

Figure 7. Electrophoresis gel depicting a transcript of
uniform bp length only when the PCR reagent mixture
contained both the second generation iDTR plasmid and
cre,, demonstrating the ability of our plasmid to undergo
recombination.

results in the reciprocal
al inactivation of
the GFP reporter gene in cre-positive cells, which remained a marker of transfection in
cre-deficient cells. The entire iDTR2 plasmid is dep
depicted below.

Figure 8. Schematic
representation of the iDTR2
plasmid, with the entire AAV
vector. LoxP and loxp2722
sites are oriented as shown.
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Receptor Detection in Cell Culture
We first tested our iDTR2 constructs in vitro,, using transient transfections in
PC12 cells to confirm the ability of a co
co-transfected cre plasmid to activate DTR
expression. As with any pilot work, a number of hurdles needed to be overcome in order
to demonstrate reliable DTR expression in cells. First, while the PC12 grew well on the
specialized Corning® plates, it did not appear that they were adequately adherent
adheren to the
glass slides (which were used for fluorescent analysis), and thus we developed a protocol
to coat the slides in type IV collagen, incubate them, and remove the supernatant solution
in order to promote adherence. The cells began adhering to the sli
slides
des and producing the
characteristic pseudopodia seen under the microscope, which were a marker for surface
adherence. We then transfected them as per the protocol outlined above.
The following images are representative of iDTR2 and cre
cre-plasmid
plasmid transfection
transfect
of
viable PC12 cells.

A

B

Figure 9. Transfection of PC12 cells with both GFP
GFPcre and iDTR2 as seen under green (A), red (B) and
combined (C) fluorescences. An overlappig of red
and green fluorescence is seen in cells transfected
with both plasmids ad expressing DTR

C

41

The cells were immunostained with a primary anti
anti-flag
flag primary antibody (to
detect DTR) and an anti
anti-mouse
mouse Alexa fluor 594 (red) secondary antibody. Figure 7A
demonstrates the GFP which is part of the cre plasmid and serves to indicate the relative
transfection rate,, and some GFP from any unflipped iDTR2 plasmid
plasmid.. Approximately 30%
of cells appear to be transfected and strong GFP signals are seen indicating adequate
expression of cre recombinase in these cell. In figure 7B,, the same cells are visualized
under red fluorescence to demonstrate binding of the anti
anti-flag
flag antibody onto a subset of
cells co-transfected
transfected with both GFP
GFP-cre and iDTR2, and which now express DTR on their
cell surfaces. Figure 7C demonstrates the relative number of cre-transfected
transfected cells that
also express DTR (via overlapping green and red fluorescence) showing that none of the
cells that express DTR (red) are free from co
co-transfection
transfection with cre (green).
In figure 10, a representative image of background red fluorescence in solo
iDTR2 or solo cre plasmid transfected cells is
demonstrated. The cells that received either a
single plasmid or no plasmid at all did not
demonstrate the bright red fluorescence seen in a
subset of the cells in image 9B
9B. Thus, no
detectable flag sequence was being produced in
these cells. In the solo cre plasmid transf
transfection

Figure 10. Representative image of singlesingle
plasmid transfected cells, or cells not transfected
with DNA, stained with anti-flag
anti
antibody.

cells, green fluorescence was demonstrated, as would be expected because of the GFP
found on the cre-plasmid,
plasmid, but no red fluorescence was seen. A weaker green was seen on
the solo iDTR2 transfected cells.
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Under higher magnification, we can see the broad expression of the DTR around
the cell surface of iDTR and cre cotransfected cells, stained with anti-flag. In
addition, the localization of the cre GFP to
the nucleus of some cells allows us to
clearly demonstrate the expression of both
signals within the same cell, and the
A

specificity of the co-location of the two.
Figures 11A and 11B. Complementary high power images of iDTR2 and GFP-cre co-transfected PC12 cells

In sum, these transient transfection
studies in PC12 cells showed that our
various iDTR constructs expressed flagDTR only in the presence of cre
recombinase.

We went on to produce

recombinant virus using these plasmid
B

constructs to test their ability to target
specific populations of interneurons in cre-expressing transgenic mice.
In parallel to our work with PC12 cells, I formed a collaboration with a researcher
from another lab to test our iDTR constructs in primary neuronal culture.

Higher

transfection efficiency and cell stability in these primary cultures, as compared to PC12
cells, permitted quantitative assays of cell ablation using a colorimetric assay.
The cultures were prepared by extracting the brains from mouse embryos,
washing them in a solution of PBS/glucose, adding 5-6 ml trypsin in three washes,
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dissociating the cells by repeated pipetting, and then plating them on polylysine-coated
plates at a concentration of ~180,000 cells per well. 1.3 ml growth media was added per
well

and

consisted

of

glucose

and

glutamine-containing

DMEM

media,

penicillin/streptomycin, sodium pyruvate and fetal bovine serum. Growth media was
changed weekly, Neurobasal (Gibco) was added for cell maintenance, and after 14 days,
the cells were transfected with our plasmid as per the protocol outlined above.
The following images were taken from the primary culture of neurons transfected
with our iDTR2 plasmid and the
GFP-cre

plasmid.

Figure

12

demonstrates a very high percentage
of

GFP-cre

indicating

a

expressing

cells,

much

higher

transfection efficiency than we were
able to achieve in the PC12 cells.
Figure 13 demonstrates a high
percentage of cells that positively

Figure 12. Neural culture transfected with GFP-cre and iDTR2.
Green fluorescence was amplified with anti-GFP and is the
product of the GFP gene on the cre plasmid.

express DTR, but also a small subset which do not. This is likely a result of necessitating
simultaneous transfection of both
plasmids in order for recombination,
transcription, translation, and protein
production and expression to occur as
planned.
Figure 13. The same transfected
neural cells as in figure 12, co-stained
with anti-flag and viewed under red
fluorescence.
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The final image in this series demonstrates the co-localization of green and red
fluorescence, and GFP and DTR,
respectively, in the neuronal culture.

Figure 14. Colocalization of GFP-cre and DTR in
primary neural culture

From

these

images,

we

observed that in two different cell
lines, and in highly controlled
experimental conditions, we were able to demonstrate selective DTR expression in only
those cells with the potentiality of being transfected with both the cre and iDTR2
plasmids. The next task in testing our system was to demonstrate greater cell death in
response to DT exposure in DTR/cre co-expressing cells than in other, control conditions.

Cell Apoptosis Assay
After we documented adequate transfection in our PC12 cells, we began
conducting cell death assays with DT administration, using the protocols described
above. With the aid of a spectrophotometer, we were able to quantify the number of
viable cells that would induce a color change in the reagents of the cell death assay and
from this measure have quantitative data demonstrating the function of our DTR/DT
system. The results of this initial work on the transfected PC12 provided uninterpretable
data, which may have been the result of the instability of this line, even under control
conditions. The results for cell apoptosis is thus demonstrated for the primary neuronal
culture.
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Transfection of primary neuronal cultures had both a higher transfection
efficiency and a lower level of background cell ddeath
eath as compared to the PC12 cells. The
following graph represents the effect of 1µM DT on these transfected neurons, as
analyzed using the same commercial cell viability assay intially tested on PC12 cells.

Figure 15. Cell death assay performed on a neuronal culture transfected with the iDTR2 and GFP-cre
GFP
plasmids, and subsequently administered DT.

The groups include singly tranfected controls, singly transfected groups with DT
administration, a doubly transfected cohort without DT, and our experimental group
transfected with both plasmids and treated with DT. The cell viability is reported
reporte relative
to the most viabile cohort, cre+water, and all other groups are reported as percent cell
viability as compared to this group. Here, we see that cre or DTR transfection alone had
some effect on cell viability but it only appears to a maximum of 20% cell loss.
Additionally, the two solo
solo-plasmid-plus-DT groups show some cell loss, but at 10% or
less. In the group transfected with both plasmids, we see a further degree of cell loss,
approximately 20% below the cre+water group. We understood from our PC12 studies
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that the greater the number of transfected pplasmids, the greater potential for cell loss
secondary to concordant lipofectamine intake and plasmid interference of normal cellular
function. Finally, we see that the group administered both plasmid and DT showed a 45%
reduction in number of viable cells as compared to the viability of the other control
conditions, which was also 25% lower than the iDTR+Cre+water group or lower than the
effect of DT alone (which appeared to be only 10%). While not total cell loss, which was
not expected from of our experi
experiments demonstrating that not all cre--transfected cells
expressed DTR, this provide
provided controlled data demonstrating that there was in fact cell
loss resulting from the implementation of our DTR/DT system. This provided the
impetus for us to move forward with our in vivo testing.

In vivo Receptor Detection
The first stereotactic virus injections were performed using our iDTR2 plasmid,
which was the first plasmid to be packaged in an AAV vector. The following images
demonstrate the loss of GFP expression in GS
GS-cre
cre mice compared to wild-type
wild
controls.

Figure 6Figure 16. Wild-type
type and transgenic GS
GS-cre
cre mice (cre expressed in glial cells) infected with our iDTR2
plasmid in an AAV vector. The loss of green fluorescence in the GS-cre
cre mice is seen compared to wild-type
wild
mice.
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The plasmid, in review, functions by flipping the inner cassette in the presence of
cre to remove transcription of the GFP gene and flip the DTR gene into a ‘forward’
orientation, so it is transcribed instead. GS-cre mice are transgenic mice which express
cre in all neural tissues. Thus, if we look at the images, the wild type mice (which contain
no cre in their cells) show clear GFP expression in discretely identifiable cells
surrounding the virus injection site. However, in the GS-cre mice, the plasmid should be
recombined in the cre-recombinase-expressing cells, the GFP should become rendered
non-transcribable and DTR should thus be expressed. In the two right images taken from
GS-cre mice, there is a distinctly different quality of the fluorescence in which individual
cells are no longer outlined and some diffuse fluorescence, secondary to the gliosis
induced by the introduction of a needle into the area, is seen. This was clearly different in
quality from the GFP expressed in the wild type mice.
While this plasmid nicely demonstrated the loss of the GFP reporter protein
during infection of neural tissue, we did not see clear immunostaining of DTR-flag
expression. Part of this may have been the result of the bulky iDTR-GFP recombination
cassette (refined in the iDTR3 plasmid) which may have limited the number of properly
oriented DTR genes that would serve as a template for transcription, or it could have been
the result of our efforts to refine a DTR-flag staining protocol that worked as well in vivo
as it did in vitro. Regardless of the cause, we understood that using this plasmid would
create additional barriers to our progress with our in vivo work, so at this point we
decided to create the 3rd generation plasmid (iDTR3) in which the recombination cassette
consisted of only the iDTR gene. This would shorten the plasmid, simplify
recombination, and hopefully provide us with stronger evidence that DTR was being
expressed in vivo.
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iDTR3
We began constructing the iDTR3 plasmid by copying the DTR-flag
flag gene from an
aliquot of our iDTR2 plasmid via PCR, treating it with klenow fragments (New England
Biolabs) andd CIP and ligating it into an AAV vector containing a stronger CMV
promoter, which has been shown to have higher transfection rates in other experimental
experime
designs. (84). E. coli were transformed, miniprep performed
performed,, and the plasmid was
digested and analyzed for proper fragment length using electrophoresis and wholeplasmid sequencing. A properly constructed plasmid was purified, copied via megaprep
(to create a supply for in vitro transfection experiments),
), and sent for packaging in an
AAV vector for in vivo experimentation
experimentation.
The improvement of this construct would be a smaller fragment length to undergo
recombination and a smaller overall plasmid size for better packaging within our viral
vector. The concept of its design is similar to our iDTR2 construct and is depicted in
figures 17 and 18. While it appeared to provide a more striaght
striaghtforward
forward method of
inducing DTR expression, we understood that

CMV

Figures 17 and 18. iDTR3 plasmid. The smaller
recombination cassette contains only a iDTR-flag gene
under cre control. The whole plasmid sequence is
additionally similar to the iDTR2 construct but with the
addition of a CMV promoter instead of the EF
EF-1α
promoter.
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it would be at the expense of an EGFP reporter gene which would serve as our marker for
transfection and infection efficiency. The new iDTR3 plasmid was tested in vitro,
demonstrated to be as efficient
ficient as the iDTR2 construct in inducing DTR expression, and
we therefore pressed on with our work to detect DTR expression in vivo.

Figure 19.. First in vivo injections of our vvirus-packaged iDTR3 construct.. Tissue was stained with anti-flag.

Figure 19 depicts our first infection of striatal tissue with our newly-packaged,
newly
shorter iDTR3 plasmid. With our flag staining protocol, were able to demonstrate DTR
expressing cells immediately surrounding the needle tract in a cohort of GS-cre
GS
mice.
Looking closely, staining on the periphery of individual cells can be seen, similar to the
staining pattern demonstrated in the PC12 and primary neural cells, making us confident
that membrane-bound
bound DTR was express
expressing in cre- containing cells infected
infe
with our
capsid-bound plasmid.
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Additionally, figure 20 demonstrates the staining of DTR expressing cells
immediately surrounding the injection site, but no staining at its periphery. While this
nicely demonstrated the specificity of the immunostaining, and led us to believe that we
were seeing true DTR expres
expression, we were unsure as to why the infectivity was so

Figure 20. Close-up
up of injection site of iDTR3 virus demonstrating anti
anti-flag
flag staining only at the injection site and not
at the periphery of the slice.

localized, and we hoped we would be able to demonstrate more diffuse infectivity in
future experiments. We worked to this end by increasing the volume of virus injection
and by using our newly acquired microsyringe infusion pump for a steady and continuous
infusion rate.
ChAT
mice
Images 21 and 22 demonstrate our next experiment in which ChAT-cre
(with cre expression in choline acetyltransferase cell
cells) were injected with our iDTR3
plasmid in one of their striata, and saline on the contralateral side
side. ChAT interneurons
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were

stained

with

a

red

fluorescent anti-ChAT antibody
in order to demonstrate the
distribution of these cells in the
striatum and green anti-DTR to
demonstrate

any

DTR

expression. In figure 21, the red
fluorescence of the native ChAT
cells in the right striatum is
demonstrated, after this side was

Figure 21. Anti-ChAT staining of saline-injected striatal tissue. No
DTR staining is demonstrated in these cells.

injected with saline to serve as a control. However, no true green fluorescent anti-DTR
antibody is staining these cells (the green streaks are artifact seen in all slices). In the
same mouse, figure 22 shows
the contralateral striatum where
virus was injected. In this
image, we see roughly the same
distribution and red fluorescent
staining of the ChAT cells as the
contralateral,

control

side.

However, on this virus-infected
side, we also see the coFigure 22. Anti-ChAT (red) and anti-DTR (green) staining of iDTR3
virus-injected tissue.

localization of green fluorescent

DTR staining on these ChAT interneurons. In fact, there are cells toward the right and
left sides of the image, beyond the suspected infectivity area, which only demonstrate red
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staining for choline acetyl- transferase, but not green fluor 488 for DTR, as they may
have been beyond the range of viral infectivity. Those in the center at the injection site
are co-localizing the stains for both red and green fluorescence, demonstrating the
specific expression of DTR only in these cre-expressing, transgenic ChAT interneurons.
We were confident our iDTR3 plasmid worked to express DTR in vivo.

Neuronal Ablation
The work thus far was mostly performed during my research fellowship year, and
as clinical responsibilities drew me away from the laboratory, progress was made to
confirm neuronal ablation within the stratum and early steps have been taken to show the
behavioral effects of these ablations.
In parallel with the development of this virus-mediated ablation strategy, we
explored a simpler, though messier, strategy to achieve ChAT interneuron ablation in
mouse striatum. It is our hope that this will produce convergent results with the virusmediated strategy, strengthening the result. A specialized immunotoxin, anti-ChATsaporin, targets the proteinaceous saporin toxin specifically to ChAT-expressing neurons
to induce cell ablation directly and understand further the behavioral manifestations of
interneuron loss.
Saporin is a toxin which was first discovered in 1983 from the seeds of the
Saponaria officinalis plant, and is also commonly known as ribosome inactivating
peptide. It removes a single adenine base from the larger unit of a ribosome, completely
inactivating it. It has been coupled to antibodies and has been used as a targeted
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immunotoxin in a variety of studies. By purchasing this saporin-delivery ChAT antibody,
we could test the consequences of the exact phenomenon we were trying to replicate.
Figure 23 was prepared by a Meiyu Xu demonstrating the unilateral injection of chat-sap
toxin, with contralateral saline, in a wild-type mouse.

Figure 23. Interneuron ablation demonstrated with ChAT-saporin immunotoxin. Saline was injected on
the left side of this image and toxin on the right. Red and green dots were overlain by a computer
program to allow for clear tagging of viable cells on either side.

Using a computerized algorithm for detecting changes in staining gradients, our
lab was able to test a novel staining technique for detection of ChAT interneurons, while
clearly demonstrating the consequences of immune-delivered saporin toxin on these
dispersed interneurons within the striatum, as evidenced by figure 23. Indeed this image
is what we strove toward with our DTR/DT model, but our focus was still to regulate
such neuronal ablation using our DTR delivery system so that a timed ablation could be
performed distantly from operative trauma and nonspecific gliosis (both of which are
seen in the toxin-infused side in the image above), and so that the developmental and
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compensatory effects of this neuronal ablation, as mediated by our DTR/DT system,
could be better understood. Our methodology would also allow for us to target different
neuron types in the future, flexibility that we would not have with this ChAT-sap virus.
The initial behavioral comparison of these animals to their saline-injected siblings
demonstrated some changes in the inhibition of prepulse two weeks post-operatively, but
the sample size was small, our focus was still to demonstrate these changes using our
DTR/DT system, and newer PPI data in the most recent cohort of mice injected with our
iDTR3 virus was subsequently obtained. The immunohistological images of neuronal
ablation in these mice are demonstrated alongside their behavioral data in the following
section.

Prepulse Inhibition in Virus-Injected Mice
The preliminary experiment using our iDTR3 virus (with subsequent DT)
provided exciting initial correlations between immunohistochemical evidence of neuronal
ablation and behavioral consequences in PPI, demonstrating that our system worked as
planned. This experiment was performed in the last two months and is the newest data
compiled for this project.
While our lab was only in possession of nine chat-cre mice, I performed all
surgeries within a couple days of meeting with Dr. Pittenger to discuss continued
involvement in this project. Baseline PPI behavioral assays using the exact protocols
described earlier were performed on all nine mice before undergoing surgery. All were
injected with 1 µl of the iDTR3 plasmid in an AAVrh10 viral vector bilaterally, for a
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total volume of 2 µl virus per mouse. Coordinates were the same as previously described
and no untoward events occurred during any of the surgical procedures or during postoperatively recovery. 40ng DT was diluted in 300ml saline and injected in five of the
nine mice immediately after the 2-week post-operative PPI assay (mice #3,4,5,6,7) each
day for 3 days. This high dose of DT proved to have non-specific effects on startle
(which will be described in detail below), problematizing the interpretation of PPI
changes in these 5 mice. Therefore, at five weeks post-operatively, after obtaining 3 full
weeks of behavioral analyses for the five high dose DT mice, we decided to inject two of
the four remaining DT-naïve mice with a lower dose of DT (4ng in 300ml saline, given
just once to mice #1 and #2). This lower dose of DT proved not to have any of the nonspecific effects on startle but was sufficient to ablate the DTR-expressing interneurons
(see below). We tested whether this lower DT dose would alter behavior in a specific
manner by reducing PPI, but not the startle amplitude in response to the loud auditory
stimulus. Therefore, of the nine original mice available to us in this pilot experiment, five
had high dose DT injections (40ng x 3 days) at 2 weeks post-operatively, two had low
dose DT at 5 weeks post-operatively (4 ng x 1 day) and two were only injected originally
with the virus and not any DT post-operatively (mice #8 and #9) in order to serve as
controls.
PPI was assayed two weeks post operatively, after a pre-operative PPI, and then
for several additional weeks after DT administration. The results of the prepulse data for
the five weeks in both groups of mice are shown in graph 1.
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injected mice. Four mice were not injected with DT, and fiv
five
e were treated with highhigh
Graph 1. PPI data for virus-injected
dose DT at two weeks post-operatively.
operatively.

First, the data demonstrate an improving PPI at two weeks that plateaued and
remained stably prominent for five weeks post-operatively in the four control mice. In
addition, there was a stepwise increase of PPI for the control mice with increasing
prepulse stimulus amplitude, as is commonly seen. In the controls who never received
DT, we observed no long term deficits in PPI as a result of the vector
vector-delivery
delivery surgery.
High-dose
dose DT mice had a lower baseline PPI values as compared to the control
cohort. This was unfortunately unavoidable due to our limited number of available mice
and a result of the difficulties in separating mice housed in the same cages into different
experimental
imental conditions in an attempt to equalize the groups at baseline. The difference,
difference
in baseline PPIs between the control and DT mice was most divergent at the 12 db level
but the standard errors of the mean were overlapping for both of the other two prepulse
prepu
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conditions. At two weeks post
post-op, before the high-dose
dose DT administration, the PPI
increased for the ‘DT’ cohort and it more closely resembled the two week PPI of the
control mice.
Immediately after the 2 week PPI for the five high-dose
dose DT mice, DT was
administered to them over the course of three days as outlined above. Therefore, their
first PPI analysis after DT administration was at 3 weeks. There appears to be a small
decline in PPI from week 2 to 3 for th
these
ese mice, possibly due to some initial DT effects.
At 4 weeks, this PPI deficit became more pronounced. While there appears to be a slight
recovery at 5 weeks, it was not quite at baseline levels, and was certainly not near the
high plateau level as seen w
with
ith the control mice at this week of analysis. While not a
striking PPI reduction, there certainly appeared to be some effect of DT administration on
PPI. Looking at the PPI over the course of these weeks for some of the individual DTDT
injected and control mouse certainly did, however, demonstrate some effect on PPI with
DT administration on an individualized level. Mouse 3 received DT at the point in time
denoted by the arrow and mouse 8 was a control
control, as shown in figure 24.

Figure 24. PPI data for individual mice. Mouse 3 was treated after we
week
ek 2 PPI as denoted by the arrow and mouse
8 was not treated with DT at all after iDTR3 virus injection.
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Unfortunately, an unexpected reduction in startle amplitude was demonstrated in
the DT mice the first week after DT administration as demonstrated in graph 2.
2 This was
surprising; our work with DT up to this point had demonstrated no gross behavioral
change in other cohorts of mice, nor was there evidence for any overt behavioral changes
when observing these mice. This data was disconcerning because we were now unsure of
whether the PPI reduction in the DT mice was in fact due to neuronal ablation or the
effects of DT on the complex sstartle
tartle circuitry in general. Prepulse inhibition of startle
response to loud stimuli after hearing ‘premonitory’ lower amplitude sounds is difficult to
assess when low baseline startle amplitude results from the high amplitude stimuli
delivered on their own.

Graph 2. Startle data for AAV-injected
injected mice. Startle reductions in high
high-dose
dose DT treated mice confounded our PPI
data and left us unsure as to whether DT effects or interneuron ablation were the cause for PPI reductions. Blocks
denote separate and sequential
uential periods of startle recording to pulse
pulse-only conditions.
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To test the nonspecific effect of this high dose of DT on startle and PPI, we
administered high-dose
dose DT to wild
wild-type
type mice that had not been injected with the AAV
virus. This would demonstrate to us whether the DT was in fact the cause of the startle
reduction and whether it also reduced PPI in the absence of AAV virus injection. The
data obtained in this analysis is presented in the two following graphs.

Graph 3. Startle data for high-dose
dose DT injected wild type mice which received no AAV virus. Startle reductions are
seen similarly to those seen in the cohort of AAV
AAV-injected mice. Blocks denote separate and sequential periods of
startle recording to pulse-only
only conditions.

Wee saw the same redu
reduction
ction in startle amplitude in these wild type mice the first
week after their DT administration (demonstrating to us that the DT was likely the cause
of reduced startle).. DT in fact had some role in disrupting the complex startle circuitry;
however, with startle
tartle values in the 100
100-300
300 range, we investigated whether there was also
a change in PPI for these mice
mice, in order to determine if the DT was in fact the cause of
PPI reduction seen in the AAV
AAV-injected mice.
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Graph 4 presents the PPI analysis for these hig
high-dose
dose DT wild type mice. There
appeared to be no loss of PPI in these mice after DT administration. This encouraged us
to think that, despite its effects on startle, high
high-dose
dose DT did not necessarily reduce PPI on
its own in wild-type
type mice. Rather, this pprovided
rovided some evidence for the notion that PPI
reduction seen in virus--injected mice after high-dose
dose DT might indeed represent a
specific effect of neuronal ablation, albeit confounded by the reduction in baseline startle.

Graph 4. PPI data for high-dose
dose DT injected wild type mice. Despite the small n, there appeared to be an
improvement in PPI up to four weeks post
post-operatively, in contrast to the virus-injected mice.

As described above, we administered a lower dose of DT to two of our control
mice (#1 and #2) five weeks post
post-operatively in an effort to achieve interneuron ablation
without affecting baseline startle.
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PPI data for the late, low
low-dose DT injected mice are presented in figure 25 below.
These mice received the same surgery at week 0 as the other transgenic mice of this
experiment. No intervention was performed on them from weeks 11-5,
5, except for the PPI
analyses that provided data for left
left-most points on these
ese graphs. Then, after the week 5
PPI, the mice were injected with the 4ng DT as described. This produced a striking effect
noted in mouse 1, but no overt effect on PPI in mouse 2. The causes of which were
further examined in an immunohistological analyse
analysess of the brains of these mice.

Figure 25. PPI data for the two mice injected with low
low-dose
dose DT, five weeks after bilateral AAV virus injection

Using DAB staining to identifying the ChAT interneurons, and observing the
specimens under light microscopy, we were
re able to clearly see the dark staining pattern
of the ChAT interneurons. In Figure 26 on the following page, the immunohistochemical
data for control mouse ##8 is demonstrated alongside its PPI data.
a. No reduction in the
number of striatal ChAT interneurons is documented in this mouse and the PPI is
prominent and stable, as was previously demonstrated in this section.
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Figure 26. Immunostaining of the striatal ChAT interneurons
in control mouse #8 injected with AAV but not with DT.

In figure 27, the data is presented for
mouse 3, which received high
high-dose DT 2 weeks post-operatively.

Figure 27. Immunostaining of the striatal ChAT
interneurons in mouse #3, injected with AAV
and then high-dose
dose DT 2 weeks postpost
operatively
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Next, we examined the immunohistochemistry of the two low
low-dose
dose DT injected
mice in order to determine the cause for a reduction in PPI in mouse #1 but not in mouse
#2. The striatal image for mouse #1 is presented in figure 28, demonstrating an ablation
of a substantial portion of ChAT interneuron
interneurons localized in the dorsomedial striatum, but a
relative preservation of inter
interneurons
neurons in more lateral regions. This ablation could possibly
most resemble findings of interneuron loss in patients with TS, w
where
here only a 50-60%
50
reduction has been seen.

Figure 28. Immunostaining of the striatum of mouse #1
which was injected with low-dose
dose DT 5 weeks postpost
operatively. The loss of interneurons appears to be
localized in the dorsomedial striatum.

Finally, the data for mouse #2 are presented in figure 29. There appears to be a
relative preservation of the striatal interneurons, like
likened
d to the data for the control mouse
#8. It is possible that the virus was not originally injected on target to the striatum in this
mouse, the DT did not
ot properly apoptose the infected interneurons, or there was yet
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another reason why these neurons were not ablated, but despite these potentialities, the
PPI data in this mouse is consistent with the documented ineffective ablation of these
interneurons as seen on immunohistochemistry
immunohistochemistry. The data for this mouse, compared
closely with mouse #1, demonstrated that PPI behavioral changes correlated
correlat with the loss
of the interneurons thought to regulate this behavior in striatum. Our
ur group was excited
by these new findings which were the fi
first to demonstration the full efficacy of our
DTR/DT system in vivo.

Figure 29. Immunostaining of the striatum of
mouse #2 which was injected with low-dose
low
DT
5 weeks post-operatively. No substantial loss of
interneurons correlated with the intact PPI
behavior.
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IV. Discussion

Tourette syndrome is a highly complex human neuropsychiatric disorder which, for
some individuals, creates a high degree of morbidity. Recent findings demonstrate a
specific and significant 50-60% reduction of striatal interneurons in individuals who
experienced the most severe forms of the sensorimotor-gating disruption associated with
TS and its related disorders. Viral vector-mediated gene delivery is a technological
achievement, which when used in transgenic mice, allows for a cell-type specificity never
before realized. Its application for modeling the pathophysiological findings in TS, which
implicate striatal interneuron loss in sensorimotor dysfunction, will allow us to
understand the neurocircuitry of the striatum in unprecedented ways. This model will also
allow us to observe naturally-occurring compensatory mechanisms surrounding the
disruption of these regulatory cells, as well as understand the downstream neurochemical
changes which may one day drive the development of novel therapeutics aimed at
correcting symptomatology in Tourette syndrome.
Studying previously established protocols for assessing pharmacological effects on
behavioral PPI data can also inform the direction of future studies, such as testing the
effects of anti-psychotic medications on this mouse model in development. (85, 86) This
work will undoubtedly be performed in parallel to further behavioral characterization of
these mice. As we understand more about the circuitry of PPI, now thought to reside in
the limbic cortex, striatum, pallidum and pontine tegmentum, we can begin to tease apart
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the function of each nucleus in this circuit, understand exactly what role our lesions are
having, and where pharmacological therapeutics can intervene. (87)
I took a lead role in performing a majority of the work throughout the course of this
project. Testing of the iDTR1 construct occurred before my time in the lab, but I
constructed both the iDTR2 and iDTR3 plasmids, tested them extensively in vitro and in
vivo, and performed behavioral analyses on the first cohort of iDTR3-injected mice.
Mouna Basr performed the in vitro testing of the iDTR2 plasmid in primary neuronal
culture and the subsequent MTT cell death assay on these cells. Meiyu Xu helped in the
planning of the in vitro and in vivo testing of both the iDTR2 and iDTR3 plasmids, and
performed the saporin toxin injections on the wild type mice on her own. Other than these
exceptions, I conducted the remainder of the work detailed in this report.
I greatly valued my experience working on this project and it was a personal
accomplishment to demonstrate such striking correlation between behavioral assays and
relative degrees of interneuron loss on immunohistochemistry in this small cohort of
mice. For me, it truly brought this project full circle.
While some PPI effects may have been diluted between the individual mice within
the larger groups of mice, the utility of analyzing data for individual mice became
evident. In fact, while the pooled PPI data for mice #1 and #2 in the low dose-DT
experiment did not show a difference from that of the control cohort, it was only when
we looked at mouse #1 separately from mouse #2 were we able to see a reduction in PPI
for mouse #1, and then correlate it with the immunohistochemistry of the mouse’s brain.
There were several possible reasons why mouse #2 did not show neuronal ablation
with low dose DT, including inaccurate stereotactic injection of the virus at week 0,
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ineffective DTR expression in its interneurons, or just the ineffectiveness of low-dose DT
in some mice. The relative metabolism of this toxin in different mice and its relative
variability in permeating the blood-brain barrier may be two causes for its differential
efficacy between mice. More work remains to be done to study the effects of simian DT
on our system, as well as in physiological-unique mice.
We did, however, learn a great deal about DT administration from our wild-type
control experiment. While previously unknown, we discovered that high-dose DT has a
significant impact on startle response during PPI analysis. As a result, it is difficult to
attribute PPI changes in virus-injected mice which subsequently received high-dose DT
solely to interneuron ablation. Other behavioral factors may come into play, and as a
result of our ever-evolving hypotheses, we learned to refine our experiment to include a
low-dose DT injection, which appeared to in fact still work to induce apoptosis in cells
expressing the DT receptor on their surfaces.

Further Studies
Other work yet to be performed includes further PPI analysis in a larger
population of WT mice given high- and low-dose DT in order to determine whether any
real deficits in startle or PPI presents in these mice. This is a necessary experiment to
demonstrate first that there are no observable effects on PPI or startle in mice given lowdose DT. Secondly, it may prove useful in the future to understand what effect high-dose
DT is having on behavior in a mouse, where the changes are occurring neurobiologically
(using immunohistochemistry to survey suspected nuclei in the startle circuit), why there

68

appear to be no changes in PPI, and whether the startle reduction seen is only a transient
phenomenon.
In addition to testing and further understanding the subtle behavioral effects of
DT administration, another larger cohort of mice will be injected with the AAV-iDTR
virus in order to replicate findings from this current experiment and optimize conditions
for interneuron ablation (this is actually already underway). Additionally, the PPI data
will be looked at very closely on an individual basis in this new cohort in order to further
determine any dose-response correlation that may exist between interneuron loss as seen
by immunohistochemistry and quantitative deficits documented in PPI behavior. It would
indeed be a fascinating finding to demonstrate a stepwise degree of PPI dysfunction with
quantitated neuronal loss, or loss localized to a specific striatal region. This larger cohort
will also serve as the basis to further study the generation of ChAT interneuron-deficient
mice both behaviorally and pharmacologically to determine the efficiency of this model,
its responsiveness to antipsychotics and amphetamine, and its predictive validity in
replicating the symptomatology of TS.
The additional behavioral analyses to be undertaken in DT-administered, virusinjected mice will included the use of a Cleversys apparatus in order to systematically
observe any behavioral effects on the mice which may produce repetitive, stereotypic
behavioral, similar to that of TS. The Cleversys apparatus monitors the details of each
mouse’s movements over the course of 24 hours and is a highly sophisticated movementtracking program which catalogues each of the mouse’s behaviors. It has an extraordinary
capacity to document even the most subtle increases in stereotypic behavior between
different cohorts of mice. While some individuals with TS demonstrate severe and overt
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ticcing behaviors, there are in fact many subtle gradations of behavioral manifestation
which require a highly sensitive observer in order to reliably qualify and quantify. The
Cleversys apparatus will serve this purpose, as highly-trained clinicians do for individuals
with TS.
In addition to this analysis, it would be useful to observe cohorts of mice from
subsequent experiments in an elevated-plus maze and an open field analysis. The former
documents the amount of time a mouse spends on an open platform two feet off the
ground as compared to closed platforms on the same structure, organized in a “plus”
shape. This is a well-documented behavioral assay that has been used to assess anxietylike behaviors in mice. (88, 89) It is conceivable that with changes in the fear-induced
startle response, changes in other emotionally-related systems may also occur.
Additionally, the open field analysis is performed by placing the mouse in a square box
and using software to assess the video of a 5-minute trial of this mouse in this box. The
amount of time the mouse spends in the periphery of the box, as compared to its center,
has been used as a relative measure of anxiety-like versus exploratory-like behaviors in
various mouse models. (90) These two tests will provide useful information regarding the
anxiety-like behaviors of the virus-injected mice and determine if in fact startle of PPI
data can in any way be influenced by the differences in anxiety between the cohorts of
mice.
The use of amphetamines has also been used to induce tic-like behaviors in mice. (91)
Testing the response of experimental mice in our model with amphetamines may provide
insight into the sensorimotor gating abnormalities in these mice, and may accentuate
more subtle behavioral changes related to TS.
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With further reliability of behavioral testing, mice will also be administered
medications classically known to reduce symptoms in TS, such as typical and atypical
antipsychotics. This measure would allow us to further validate the face validity of our
model and demonstrate a degree of predictive validity in support of trialing novel
therapeutics for the alleviation of symptoms, similarly to the effects of the antipsychotic
medications on patients with Tourette syndrome.

Limitations
The biggest limitations imposed on me during the course of this study were time and
availability of transgenic mice. This was originally planned to be a several year project,
and while we were able to achieve much in the 18 months chronicled in this report, there
is a great deal that still remains to be done. It is wonderful that behavioral consequences
of our DTR/DT system are just now being documented and correlated to interneuron loss,
but indeed I look forward to taking time over the next few months to increase the sample
size of the virus injected mice, optimize further DT administration in order to minimize
any unwanted behavioral consequences, localize injection to different parts of the
striatum (dorsal and lateral), and steadily demonstrate behavioral changes across several
cohorts of mice alongside their immunostaining data. Additionally, strain differences
between control mice and our transgenic mice could result in different behavioral
responses as seen on PPI. This study is also limited in its goals to produce a model for a
highly complex, cognitive as well as sensorimotor disorder, which can only fully be
experienced in a human. While symptom such as tics and PPI dysfunction can be
replicated, the internal cognitive and emotional struggle faced by patients, which also
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interact and change behavioral manifestations, can never be modeled fully in mice.
Finally, while we can observe DTR expression in infected interneurons, and then
interneuron loss after DT administration, these are only indirect ways of understanding
exactly what mechanisms are occurring at the cellular level to truly cause these apoptotic
events. While it appears our hypotheses are correct, and result in our predicted outcomes,
I am certain that there remains much we do not understand regarding what is occurring at
the cellular and subcellular levels. As we replicate this interneuron loss more in the
future, we will further investigate some of the mechanisms and downstream effects
taking place.

Conclusion
We were able to engineer several AAV-vector plasmids which utilized sophisticated
recombination techniques to allow for the selective expression of the DTR gene in the
presence of cre. We were able to use the genetic machinery of PC12 cells, as well as
primary neural culture cells to demonstrate effective DTR expression after transfection of
this construct into these cells. In addition, translation of this work was performed
demonstrating the effectiveness of the DTR-expressing system in vivo as well. Finally,
we are starting to document real behavioral modifications induced through the genetic
engineering and ablation of a small population of interspersed interneurons that comprise
only 1% of the total volume of the striatum. We have been fortunate enough to describe
these behavioral changes side-by-side with images demonstrating the loss of ChAT
interneurons in our small pilot study of nine mice. This finding is quite exciting, unique
in its quite novel methodology, and will surely fuel work on this project for years to
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come. Further directions can include investigating the potential of this system to ablate
other populations of interneurons and understand the downstream effects on global
striatal activity.
I am grateful to have work on such an interesting and internally-motivating project in
an environment such as Dr. Pittenger’s lab. I valued the time spent working with Meiyu
Xu and the guidance provided to me during the course of this work by Dr. Pittenger.
Especially during the several months when I took the lead role on this initiative while
Meiyu was away on maternity leave, Dr. Pittenger’s support was unparalleled and it
provided me the self-confidence to manage such complex work and produce results that
propelled it forward. I am certain that the skills I gained during this year will allow me to
further study the use of viral vector-mediated gene therapy in the future and advance its
use in correcting identified neuropathophysiology in any number of other psychiatric and
neurological disorders. It is certainly one of the most rewarding experiences of my time
at the Yale School of Medicine.
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